Trial Profile

A randomised, placebo-controlled trial investigating the role of fampiridina in cerebral circuits involved in cognitive and motor function of patients with multiple sclerosis.

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 29 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fampridine (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use

Most Recent Events

22 Jul 2019 Results assessing effectiveness of dalfampridine for the symptomatic treatment of CogIm in multiple sclerosis published in the Neurology
13 Oct 2017 This study has been completed in Italy as per European Clinical Trials Database.
28 Apr 2017 Primary endpoint (Improvement in the SDMT score) has been met, according to results presented at the 69th Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com